To date, four HDAC inhibitors, vorinostat, romidepsin, panobinostat, and belinostat, have been approved by the United States Food and Drug Administration and are used for hematologic cancers in clinic (Yoon and Eom, 2016). Here, HDAC9 is linked to hematopoietic and lymphoid cell neoplasm.